Skip to main content
SpringerLink
Log in
Book cover

Antiviral Chemotherapy 4 pp 257–269Cite as

ddC (Zalcitabine)

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 394))

Abstract

ddC (zalcitabine) is one of four nucleoside analogs currently approved by the Food and Drug Administration for the therapy of HIV infection. Despite its narrow therapeutic ratio, ddC has demonstrated in vivo activity against HIV disease, both alone and in combination with other drugs including AZT (zidovudine) and the protease inhibitor saquinavir.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. H. Mitsuya, S. Broder. Inhibition of the in vitro infectivity and cytopathic effect of human T-Iymphotrophic virus type IIUlymphadenopathy-associated virus (HTLV III/LAV) by 2’,3’-dideoxynucleosides. Proc Natl Acad Sci. USA. 83: 1911–1915 (1986).

    Article  CAS  Google Scholar 

  2. W-Y. Gao, T. Shirasaka, D.G. Johns, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest. 91: 2326–2333 (1993).

    Article  PubMed  CAS  Google Scholar 

  3. W-Y. Gao, R. Agbaria, J.S. Driscoll, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2’,3’-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 269: 12633–12638 (1994).

    PubMed  CAS  Google Scholar 

  4. C-F. Perno, R. Yarchoan, D.A. Cooney, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GMCSF) potentiates viral production yet enhances the antiviral effect mediated by 3’-azido-2’,3’-dideoxythymidine (AZT) and other dideoxynucleosides. J Exp Med. 169: 933–951 (1989).

    Google Scholar 

  5. J.J. Eron, V.A. Johnson, D.P. Merrill, et al. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2’,3’-dideoxycytidine in vitro. Antimicrob Agents Chemother. 36: 1559–1562 (1992).

    Article  PubMed  CAS  Google Scholar 

  6. M.W. Vogt, A.G. Durno, T-C. Chou, et al. Synergistic interaction of 2’,3’-dideoxycytidine and recombinant interferon-a on replication of human immunodeficiency virus type 1. J Infect Dis. 158: 378–385 (1988).

    Article  PubMed  CAS  Google Scholar 

  7. V.A. Johnson, D.P. Merrill, T-C. Chou, et al. Human immunodeficiency virus type 1 (HIV-I) inhibitory interactions between protease inhibitor Ro 31–8959 and zidovudine, 2’,3’-dideoxycytidine, or recombinant interferon-a against zidovudine-sensitive or -resistant HIV-1 in vitro. J Inf Dis. 166: 1143–1146 (1992).

    Article  CAS  Google Scholar 

  8. K-T. Chong, P.J. Pagano, R.R. Hinshaw. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3’-Azido-3’-Deoxythymidine or 2’,3’-Dddeoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother. 38: 288–293 (1994).

    Article  PubMed  CAS  Google Scholar 

  9. M.W. Vogt, K.L. Hartshorn, P.A. Furman, et al. Ribavirin antagonizes the effects of azidothymidine on HIV replication. Science. 235: 1376–1379 (1987).

    Article  PubMed  CAS  Google Scholar 

  10. M. Baba, R. Pauwels, J. Balzarini, et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2’, 3’dideoxynucleosides but enhances inhibitory effects of purine 2’,3’-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 31: 1613–1617 (1987).

    Article  PubMed  CAS  Google Scholar 

  11. R.Yarchoan, C.R. Perno, R.V. Thomas, et al. Phase I studies of 2’, 3’ dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1, 7681 (1988).

    Google Scholar 

  12. T.C. Merigan, G. Skowron, S. Bozzette, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus infections. Annals Int Med. 110: 189–94 (1989).

    Article  CAS  Google Scholar 

  13. A.R. Berger, J.C. Arezzo, H.H. Schaumburg, et al. 2’,3’-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology. 43: 358–362 (1993).

    Article  PubMed  CAS  Google Scholar 

  14. T.C. Merigan, G. Skowron and the ddC Study Group of the AIDS Clinical Trials Group of the NIAID. Safety and tolerance of dideoxycytidine as a single agent. Amer J Med. 88 (suppl 5B): 11S - 15S (1990).

    Article  PubMed  CAS  Google Scholar 

  15. M. Gottlieb, J. Galpin, J. Thompkins. 2’,3’-dideoxycytidine (ddC) in the treatment of patients with AIDS and ARC (abstract). Fifth International Conference on AIDS, Montreal, Canada, June 4–9, 1989.

    Google Scholar 

  16. R.W. Klecker, J.M. Collins, R.C. Yarchoan, et al. Pharmacokinetics of 2’,3’-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol. 28: 837–842 (1988).

    Article  PubMed  Google Scholar 

  17. Hoffman La-Roche, letter to investigators, December 23, 1991.

    Google Scholar 

  18. M.A. Fischi, R.M. Olson, S.E. Follansbee, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Int Med. 118: 762–769 (1993).

    Article  Google Scholar 

  19. M. Fischi, K. Stanley, A. Collier, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med. 122: 24–32 (1995).

    Article  Google Scholar 

  20. Food and Drug Administration, Transcript of the Antiviral Drug Products Advisory Conunittee Meeting, September 20, 1993.

    Google Scholar 

  21. D.I. Abrams, A.I. Goldman, C. Lauver, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med. 330: 657–662 (1994).

    Article  PubMed  CAS  Google Scholar 

  22. S.A. Spector, S. Blanchard, E.M. Conner, et al. Results of a clinical trial comparing two doses of 2’,3’-dideoxycytidine (ddC) in the treatment of children with symptomatic human immunodeficiency virus (HIV) infection who were intolerant or had failed zidovudine (ZDV) therapy (ACTG 138). Am Ped Soc. Abstract 1165: 197A (1994).

    Google Scholar 

  23. G. Skowron, SA Bozzette, L Lim, et al. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Int Med 1993; 118: 321.

    Article  PubMed  CAS  Google Scholar 

  24. S. Bozzette, G. Skowron, J. Arezzo,. ACTG 050: Alternating (ALT) and (INT) ddC and AZT in the treatment of persons with advanced HIV infection and hematologic intolerance to AZT. Sixth International Conference on AIDS, San Francisco, CA, June 20–24, 1990, abstract S.B.425.

    Google Scholar 

  25. P.A. Pizzo, K. Butler, F. Balis, et al. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J Ped. 117: 799–808 (1990).

    Article  CAS  Google Scholar 

  26. B-YT. Nguyen, L.E. Shay, K.M. Wyvill, et al. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. J Infect Dis. 168: 810–817 (1993).

    Article  PubMed  CAS  Google Scholar 

  27. M. Liu, J.L. Fahey, N. Aziz, et al. Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. J Infect Dis. 170: 1165–1171 (1994).

    Article  PubMed  CAS  Google Scholar 

  28. D.D. Richman, J.M. Grimes, S.W. Lagakos. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immuno-deficiency virus. J AIDS. 3: 743–746 (1990).

    CAS  Google Scholar 

  29. D.D. Richman, M.A. Fischi, M.H. Grieco, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS-related complex: a double-blind, placebo-controlled trial. N Eng J Med. 317: 192–197 (1987).

    Article  CAS  Google Scholar 

  30. T-C. Meng, M.A. Fischi, A.M. Boota, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Int Med. 116: 13–20 (1992).

    Article  PubMed  CAS  Google Scholar 

  31. D.D. Richman, T-C. Meng, S.A. Spector, et al. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J AIDS. 7: 135–38 (1994).

    CAS  Google Scholar 

  32. R. Schooley, B. Larder, M. St. Clair,. Combination antiretroviral therapy in previously untreated individuals. Wellcome Foundation Symposium, Yokohama, Japan. August 7, 1994.

    Google Scholar 

  33. R. Bassett, D. Schoenfeld, A.C. Collier for the ACTG 229 Protocol Team. ACTG 229 Executive Summary. May 26, 1994. Division of AIDS, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

    Google Scholar 

  34. A.C. Collier, R.W. Coombs, J. Timpone,. Comparative study of Ro31–8959 and Zidowdine (ZDV) vs. ZDV and Zalcitabine (ddC) vs. Ro 31–8959, ZDV, and ddC. 10th International Conference on AIDS, August 7–12, 1994, Yokohama, Japan, abstract 058B: 21.

    Google Scholar 

  35. T. Shirasaka, R. Yarchoan, M.C. O’Brien, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci. 90: 562–566 (1993).

    Article  PubMed  CAS  Google Scholar 

  36. J.E. Fitzgibbon, R.M. Howell, C.A. Haberzettl, et al. Human immunodeficiency virus type 1 poi gene mutations which cause decreased susceptibility to 2’,3’-dideoxycytidine. Antimicrob Agents Chemother. 36: 153–157 (1992).

    Article  PubMed  CAS  Google Scholar 

  37. J.E. Fitzgibbon, A.E. Farnham, S.J. Sperber, et al. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol. 67: 7271–7275 (1993).

    PubMed  CAS  Google Scholar 

  38. D.D. Richman, J.M. Grimes, and S.W. Lagakos. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS. 3: 743–746. (1990).

    CAS  Google Scholar 

  39. R. Schuurman, M. Nijhuis, R. van Leeuwen, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 171: 1411–1419. (1995).

    Article  PubMed  CAS  Google Scholar 

  40. Z. Gu, Q. Gao, X. Li, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2’,3’-dideoxycytidine. J Virol. 66: 7128–7135 (1992).

    PubMed  CAS  Google Scholar 

  41. D. Zhang, A.M. Caliendo, J.J. Eron, et al. Resistance to 2’,3’dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 38: 282–287 (1994).

    Article  PubMed  CAS  Google Scholar 

  42. Z. Gu, Q. Gao, H. Fang, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2’,3’dideoxycytidine and 2’,3’dideoxy-3’-thiacytidine. Antimicrob Agents Chemother. 38: 275–281 (1994).

    Article  PubMed  CAS  Google Scholar 

  43. B.A. Larder, S.D. Kemp, and P.R. Harrigan. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 269: 696–699. (1995).

    Article  PubMed  CAS  Google Scholar 

  44. T. Shirasaka, M.F. Kavlick, T. Ueno, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci. USA. 92: 2398–2402. (1995).

    CAS  Google Scholar 

  45. M.H. St. Clair, J.L. Martin, G. Tudor-Williams, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-lreverse transcriptase. Science. 253: 1557–1559 (1991).

    Article  Google Scholar 

  46. R.W. Shafer, M.J. Kozal, M.A. Winters, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type I strains with unique patterns of pol gene mutations. J Infect Dis. 169: 722–729. (1994).

    Article  PubMed  CAS  Google Scholar 

  47. S.F. Lacey and B. A. Larder. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2’,3’-didehydro-2’,3’-dideoxythymidine in cell culture. Antimicrob Agents Chemother. 38: 1428–1432. (1994).

    Article  PubMed  CAS  Google Scholar 

  48. D. Mayers, A. Japour, J-M. Arduino, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Chemother. 38: 307–314 (1994).

    Article  PubMed  CAS  Google Scholar 

  49. MA. Sande, C.C.J. Carpenter, G. Cobbs, et al. Antiretroviral therapy for adult HIV-infected patients: Recommendations from a State-of-the-Art Conference. JAMA. 270: 2583–2589 (1993).

    CAS  Google Scholar 

Download references

Authors
  1. Gail Skowron
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria, Australia

    John Mills

  2. University of California San Francisco, San Francisco, USA

    Paul A. Volberding

  3. University of Washington, Seattle, Washington, USA

    Lawrence Corey

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media New York

About this chapter

Cite this chapter

Skowron, G. (1996). ddC (Zalcitabine). In: Mills, J., Volberding, P.A., Corey, L. (eds) Antiviral Chemotherapy 4. Advances in Experimental Medicine and Biology, vol 394. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9209-6_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9209-6_23

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-9211-9

  • Online ISBN: 978-1-4757-9209-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation